ELAN
Elanco Animal Health Incorporated · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -12.5% ·
share flow -0.6% ·
net new positions -14.3%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 130 | +5 | 426.73M | $10.50B | +12 | −6 |
| Q1 2026 | 127 | -2 | 403.59M | $9.65B | +6 | −9 |
| Q4 2025 | 128 | +1 | 433.50M | $9.81B | +4 | −2 |
| Q3 2025 | 20 | -1 | 348.71M | $7.02B | — | −2 |
| Q2 2025 | 19 | +2 | 313.01M | $4.47B | +3 | −1 |
| Q1 2025 | 14 | -2 | 167.03M | $1.75B | +1 | −3 |
| Q4 2024 | 16 | -2 | 168.00M | $2.03B | — | −2 |
| Q3 2024 | 17 | +1 | 175.40M | $2.58B | +1 | — |
| Q2 2024 | 16 | — | 207.32M | $2.99B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox ✦ | 82.92M | -0.3% | $870.67M | 0.5% | ▼ Trim | 4 | SEC ↗ |
| 2 | PRIMECAP Management ✦ | 50.22M | -1.8% | $527.35M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 3 | State Street Global Advisors ✦ (passive) | 9.25M | -11.2% | $97.15M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 8.35M | +2.1% | $87.71M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 8.35M | +2.1% | $87.71M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 6.87M | +325.5% | $72.10M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 3.89M | -2.6% | $40.85M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 3.89M | -2.6% | $40.85M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 3.89M | -2.6% | $40.85M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 3.89M | -2.6% | $40.85M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 3.31M | -15.5% | $34.73M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | Marshall Wace ✦ | 509.58K | +203.6% | $5.35M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Marshall Wace ✦ | 509.58K | +203.6% | $5.35M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 524.51K | +116.4% | $5.33M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 524.51K | +116.4% | $5.33M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 524.51K | +116.4% | $5.33M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 401.92K | -27.8% | $4.22M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 383.55K | -41.9% | $4.03M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 383.55K | -41.9% | $4.03M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 355.21K | -25.6% | $3.73M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 21 | Renaissance Technologies ✦ | 33.14K | -47.2% | $348,012 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 22 | Arrowstreet Capital ✦ | 14.73K | New | $154,686 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $154,686 | 0.0% |
Exited
| Adage Capital Partners | $21.09M | was 0.0% |
| Millennium Management | $19.27M | was 0.0% |
| Two Sigma Investments | $316,919 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 512 holders, 543.55M shares, $11.98B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 40.00K sh @ 23.40 · $935,920
Officer · GC AND CORP SEC · 4.00K sh @ 23.58 · $94,273
Director · 5.00K sh @ 21.82 · $109,100
Director · 10.00K sh @ 23.68 · $236,850
Officer · EVP and CFO · 4.20K sh @ 23.08 · $96,926
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology